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Abstract
Background: Atopic dermatitis is a chronic, allergic inflammatory skin disease that is accompanied by markedly
increased levels of inflammatory cells, including eosinophils, mast cells, and T cells. Arctium lappa L. is a traditional
medicine in Asia. This study examined whether a butanol extract of A. lappa (ALBE) had previously unreported anti-
allergic or anti-inflammatory effects.
Methods: This study examined the effect of ALBE on the release of b-hexosaminidase in antigen-stimulated-RBL-
2H3 cells. We also evaluated the ConA-induced expression of IL-4, IL-5, mitogen-activated protein kinases (MAPKs),
and nuclear factor (NF)-B using RT-PCR, Western blotting, and ELISA in mouse splenocytes after ALBE treatment.
Results: We observed significant inhibition of b-hexosaminidase release in RBL-2H3 cells and suppressed mRNA
expression and protein secretion of IL-4 and IL-5 induced by ConA-treated primary murine splenocytes after ALBE
treatment. Additionally, ALBE (100 μg/mL) suppressed not only the transcriptional activation of NF-B, but also the
phosphorylation of MAPKs in ConA-treated primary splenocytes.
Conclusions: These results suggest that ALBE inhibits the expression of IL-4 and IL-5 by downregulating MAPKs
and NF-B activation in ConA-treated splenocytes and supports the hypothesis that ALBE may have beneficial
effects in the treatment of allergic diseases, including atopic dermatitis.
Background
Atopic dermatitis is a chronic, allergic inflammatory skin
disorder characterized by pruritic chronic eczema, ele-
vated serum IgE levels, and massive cellular infiltrates,
including eosinophils, mast cells, and lymphocytes [1,2].
Because mast cells play essential roles in provoking the
pathogenesis of allergic reactions via the degranulation
process, measuring the degree of degranulation reflects
the level of mast cell activation. b-Hexosaminidase
released by these cells during this process has been
reported to be a suitable marker for determining the
degree of degranulation [3]. After an allergen triggers the
allergic reactions, allergic mediators, including histamine,
cytokines, and arachidonic acid derivatives, provoke
acute and chronic allergic inflammation responses [4,5].
Various cells involved in the allergic reaction infiltrate
the lesion. Among these, T helper 2 (Th2) cells are the
most important cell type involved in atopic dermatitis
development. Th2 cells release cytokines, such as IL-4,
IL-5, and IL-13, in allergic inflammation and atopic der-
matitis. The cytokines released by Th2 cells lead to the
proliferation and activation of both mast cells and eosi-
nophils in atopic and allergic skin inflammation, conse-
quently leading to pruritus and impaired skin barrier
function [6]. In particular, IL-4 contributes to the expan-
sion of the Th2 cell subset from naïve T cells and the iso-
type switching of B cells to produce IgE against specific
environmental allergens [7]. Cytokines, such as IL-4 and
IL-5, are representative markers of the allergic reaction,
based on their roles against allergens.
Arctium lappa L. is a popular edible vegetable cultivated
in many countries. The roots are widely used in food,
whereas the seeds are used in traditional medicine as
diuretic, antipyretic, or detoxifying agents [8]. There are
reports that A. lappa has anti-inflammatory [9], free radi-
cal scavenging [10], and antioxidant [11] activities, and
that components [12] also have desmutagenic [13] and
hepatoprotective [14] effects. Although A. lappa and its
components have these biological activities, no reported
study has evaluated the anti-allergic or anti-inflammatory
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any medium, provided the original work is properly cited.effects of A. lappa root in atopic dermatitis or the molecu-
lar mechanisms involved. We examined the butanol
extract of A. lappa (ALBE) roots because it signifi-
cantly inhibited antigen-induced b-hexosaminidase
release. Atopic dermatitis is a chronic, allergic inflam-
matory skin disorder, and we investigated both the
anti-allergic and anti-inflammatory effects of ALBE.
We examined the anti-allergic effects by checking the
release of b-hexosaminidase induced by dinitrophenyl
(DNP)-BSA in RBL-2H3 mast cells and expression
levels of IL-4 and IL-5 in primary splenocytes after
treatment with concanavalin A (ConA), which gener-
ates Th2 cytokines as in an allergic environment. We
also examined the translocation of NF-Ba n dt h e
phosphorylation of MAPKs, which are activated during
inflammation, in ConA-treated primary murine spleno-
cytes to validate the anti-inflammatory effects of ALBE.
Methods
Preparation of extract
Roots of Arctium lappa L. (1 kg) were extracted with
30% ethanol under reflux (10 L, 24 h, twice). The
extract solutions were filtered and then evaporated at
40°C under reduced pressure, yielding 88.8 g of dry
powder. Approximately 50 g of the ethanol extract were
resuspended in 1 L of water and then partitioned with
equal volumes of n-hexane, AcOEt, and n-BuOH to give
n-hexane, AcOEt, n-BuOH, and H2O fractions. The
butanolic fraction weighed 22.0 g and the sample was
named A. lappa butanolic extract (ALBE).
Cell culture and experimental animals
The RBL-2H3 rat mast cell line was obtained from the
American Type Culture Collection (Rockville, MD,
USA) and grown in minimum essential medium (MEM)
with 15% fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/mL penicillin, and 100 μg/mL streptomycin at
37°C in a humidified incubator with a 5% CO2 /95% air
atmosphere. Specific-pathogen-free 8-10-week-old male
C57BL/6 mice were purchased from Orient Bio
(Gyeonggi-do, Korea) and housed in an animal room at
a temperature of 23 ± 1°C and a humidity of 55 ± 5%,
with a 12/12-h light/dark cycle. The mice were fed a
standard laboratory diet with tap water ad libitum.
Animal care and all experimental protocols were per-
formed following the Institute for Laboratory Animal
Research (ILAR) guidelines.
Materials
The anti-dinitrophenyl (DNP)-IgE and 4-nitrophenyl
N-acetyl-b-D-glucosaminide were from Sigma-Aldrich,
DNP-bovine serum albumin (BSA) was from Biosearch
Technologies, minimum essential medium was from Invi-
trogen, fetal bovine serum (FBS) was from WelGENE,
enzyme immunoassay reagents for cytokine assays, such as
IL-4 and IL-5, were from BD Biosciences, the protein
assay kit was from Bio-Rad Laboratories, anti-pERK, anti-
ERK, anti-pJNK, anti-JNK, and anti-p-p38 were from Cell
Signaling Technology, anti-p65 and anti-p38 were from
Santa Cruz Biotechnology, anti-b-actin was from Sigma-
Aldrich, anti-a-tubulin was from Abfrontier, the ECL
chemiluminescence system was from GE Healthcare, and
the polyvinylidene difluoride (PVDF) membrane was from
Millipore. The polymerase chain reaction (PCR) oligonu-
cleotide primers were custom synthesized by Bionics
(Korea).
XTT assay for cell cytotoxicity and proliferation
Splenocyte cytotoxicity and proliferation were examined
using the XTT assay kit, according to the manufacturer’s
instructions. The spleen was removed aseptically and dis-
sociated into a single cell suspension in culture medium.
Cells (5 × 10
5 cells/well) were incubated with various
ALBE concentrations (1, 10, 100 μg/mL) in the presence
or absence of ConA at 3 μg/mL for T cell activation. After
incubating the cells for 72 h, a mixture of 25 μL of phena-
zine methosulfate (PMS; electron-coupling reagent) and
25 μL of XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide] was added to each well.
The cells were further incubated for 4 h to allow XTT for-
mazan production. The absorbance was determined with a
microplate reader at a test wavelength of 450 nm and a
reference wavelength of 690 nm.
b-Hexosaminidase release assay
Degranulation of RBL-2H3 cells was evaluated by
measuring the activity of the granule-stored enzyme-b-
hexosaminidase secreted in the extracellular medium.
Cells were cultured in 24-well plates (2 × 10
5 cells/
well) overnight. The cells were sensitized with anti-
D N P - I g E( 1 0 0n g / m L )f o r1 6ha t3 7 ° C .A f t e rw a s h i n g
the cells with TGCM buffer (136 mM NaCl, 2.68 mM
KCl, 0.36 mM NaH2PO2H2O, 1 mM CaCl2,0 . 5m M
MgCl2, 11.9 mM NaHCO3,5m Md e x t r o s e ,1g / Lg e l a -
tin, pH 7.4), they were pretreated with ALBE (1, 10,
100 μg/mL) for 30 min and then treated with DNP-
BSA (1 μg/mL) for 30 min at 37°C. Aliquots of the cel-
lular supernatant (15 μL) were transferred to 96-well
plates and incubated with 60 μL of substrate (1 mM
p-nitrophenyl-N-acetyl-b-D-glucosaminide in citrate
0.05 M, pH 4.5) for 60 min at 37°C. The cells were
lysed with 0.1% Triton X-100 before removing the
supernatant to measure the total b-hexosaminidase
activity. The reaction was stopped by adding 150 μLo f
Na2CO3-NaHCO3 buffer 0.1 M, pH 10. The absor-
bance at 405 nm was measured with a microplate
reader (Themo Labsystems). The results were pre-
sented as the percentage of total b-hexosaminidase
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Triton X-100.
Degranulation OD OD OD supernatant supernatant triton x 1   / 00   100
NA preparation and mRNA analysis by RT-PCR
Total splenocytes were plated at 3 × 10
7 cells/mL and
treated with ALBE (100 μg/mL) and ConA (3 μg/mL)
for 16 h. Total RNA from the treated cells was prepared
with the TRIzol Reagent (Invitrogen), according to the
manufacturer’s protocol, and stored at -70°C until use.
For detecting cytokines, including IL-4 and IL-5, total
RNA was extracted after stimulation and treatment. The
sequences of the primers used in this study were: IL-4
forward, 5’-ATG GGT CTC AAC CCC CAG CTA GT-
3’; IL-4 reverse, 5’-GCT CTT TAG GCT TTC CAG
GAA GTC-3’;I L - 5f o r w a r d ,5 ’-AGC ACA GTG GTG
AAA GAG ACC TT-3’; IL-5 reverse, 5’-TCC AAT GCA
TAG CTG GTG ATT T-3’;G A P D Hf o r w a r d ,5 ’-GTG
GCA AAG TGG AGA TTG TTG CC -3’,a n dG A P D H
reverse, 5’-GAT GAT GAC CCG TTT GGC TCC-3’.
Each transcript was quantified as described in the
instrument manual and normalized to the amount of
GAPDH, a housekeeping gene.
Measurement of cytokine production (IL-4 and IL-5
secretion)
For cytokine immunoassays, total splenocytes were pla-
t e da t3×1 0
7 cells/mL and treated with ALBE (100 μg/
mL) and ConA (3 μg/mL) for 16 h. Culture superna-
tants were collected and the amount of secreted IL-4
and IL-5 was measured using an enzyme-linked immu-
nosorbent assay (ELISA) using the protocol supplied by
BD Biosciences.
Subcellular fractionation
Cytosolic and nuclear extracts were prepared. In brief,
splenocytes (5 × 10
7 cells/mL) were plated into 100-mm
dishes and treated with ALBE (100 μg/mL) and ConA
(3 μg/mL) for 4 h. The harvested cells were resuspended
in 0.2 ml of buffer A (10 mM HEPES at pH 7.5, 1.5 mM
MgCl2, 10 mM KCl, 1 mM DDT, 0.1% NP-40, 0.2 mM
PMSF). The cells were lysed on ice for 15 min, and cen-
trifuged (5,000g, 5 min, 4°C). The supernatant was col-
lected as cytosolic extracts. The nucleic pellet was
washed with buffer A lacking NP-40, and resuspended
in 0.025 ml of buffer C (20 mM HEPES, pH 7.5, 25%
g l y c e r o l ,0 . 4 2MN a C l ,0 . 2m ME D T A ,1 . 5m MM g C l 2,
1 mM DDT, 0.2 mM PMSF). After incubation on ice
for 30 min, nuclear debris was spun down (13,000g,
10 min, 4°C). The supernatant was collected as nuclear
extracts. The protein concentration was measured using
a protein assay kit (Bio-Rad).
Western blotting
Total splenocytes were plated at 3 × 10
7 cells/mL and
treated with ALBE (100 μg/mL) and ConA (3 μg/mL)
for 15 min and then harvested and lysed in a lysis buffer
containing 20 mM Tris, pH 7.6, 150 mM NaCl, and 1%
Triton X-100 with a protease inhibitor cocktail. Protein
contents were measured using a protein assay kit (Bio-
Rad). Samples were diluted with 1 × lysis buffer contain-
ing 1% b-mercaptoethanol. Equal amounts of cellular
protein (50 μg) were resolved by 10% SDS-PAGE and
transferred onto nitrocellulose membranes. After block-
ing, membranes were incubated with the target antibody
and then with horseradish peroxidase-conjugated sec-
ondary antibody to IgG. Immunoreactive proteins were
visualized using the ECL Western blot detection system.
The protein level was compared to a loading control,
such as b-actin or non-phosphorylated protein.
Statistical analyses
Each experiment was repeated three or four times, and
the results of a representative experiment are shown.
The results are expressed as the means ± SEM and were
compared using Student’s t-test. A statistical probability
of p < 0.05 was considered significant (# p <0 . 0 5 ,
## p < 0.01, * p < 0.05, and ** p < 0.01).
Results
ALBE inhibits antigen-induced b-hexosaminidase release
in IgE-sensitized mast cells
Rat mast cell line RBL-2H3 cells were used to determine
the effect of ALBE on the secretion of b-hexosamini-
dase. Initially, we measured the cytotoxicity of ALBE on
RBL-2H3 cells using the XTT assay. ALBE at concentra-
tions ranging from 1-100 μg/mL did not significantly
affect the cytotoxicity in 24 h (Figure 1A). Thus, we
treated DNP-IgE-sensitized RBL-2H3 cells with ALBE
ranging from 1-100 μg/mL in subsequent experiments.
ALBE significantly suppressed the DNP-BSA induced
b-hexosaminidase secretion in IgE-sensitized RBL-2H3
cells at 1, 10, and 100 μg/mL and the effects are dose-
dependent (Figure 1B). Ketotifen fumarate, an anti-
allergic drug, also decreased the b-hexosaminidase
secretion. The results showed that ALBE significantly
inhibited antigen-induced mast cell degranulation.
Effects of ALBE on cell proliferation and cytokine (IL-4, IL-5)
secretion in ConA-induced primary murine splenocytes
We examined the effects of ALBE on ConA-induced
T cell proliferation in primary murine splenocytes for
72 h to examine the immunomodulatory effect of ALBE.
The concentration and duration of ALBE treatment with-
out ConA had no effect on splenocyte viability (data not
shown). As shown in Figure 2, ALBE significantly
increased splenocyte proliferation in ConA-treated cells
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Page 3 of 11Figure 1 Effects of ALBE on cell viability and antigen-induced b-hexosaminidase in RBL-2H3 cells. (A) The cells were treated with various
concentration of ALBE for 24 h. Cell viability was assessed using XTT assay. Absorbance was measure data at 450 nm and 650 nm. (B) The cells
were sensitized by overnight incubation with 1 μg/ml of DNP-specific IgE in medium. This DNP-IgE-sensitized RBL-2H3 cells were pre-incubated
with various concentration of ALBE for 30 min and then incubated with antigen (DNP-BSA) for 15 min in order to measure the release of
b-hexosaminidase. Each bar shows the means ± SEM of four independent experiments.
##P < 0.01: significantly different from control group
**P < 0.01, *P < 0.05: significantly different from DNP-BSA alone. KF; ketotifen fumarate.
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ined the effects of ALBE on the expression and secretion
of Th2 cytokines, such as IL-4 and IL-5, in primary mur-
ine splenocytes using RT-PCR and ELISA assays to inves-
tigate the further involvement of ALBE in Th2 functions
in the atopic dermatitis-like skin lesions. ConA-induced
IL-4 and IL-5 secretion was suppressed by ALBE treat-
ment in splenocytes (Figure 3, Figure 4). ALBE treatment
without ConA had no effect on IL-4 or IL-5 mRNA
expression (data not shown), whereas ALBE with ConA
significantly decreased the mRNA expression of IL-4 (to
55.3%) and IL-5 (to 29.0%) at 100 μg/mL, compared with
ConA-stimulated splenocytes (Figure 3A, Figure 4A). In
agreement with the RT-PCR results, ALBE inhibited the
protein secretion of IL-4 (to 13.6%) and IL-5 (to 10.8%)
under the same conditions (Figure 3B, Figure 4B). These
results suggest that ALBE had immunostimulatory effects
on T cells and meaningfully inhibited the antigen-
induced mRNA expression and production of cytokines
related to allergic and atopic reactions.
Effects of ALBE on NF-B activation and phosphorylation
of MAPKs in ConA-induced primary murine splenocytes
Increased expression of NF-B (p65) was observed in
the nucleus after treatment with ALBE plus ConA for
4 h (Figure 5). The relative intensity of NF-B( p 6 5 )
translocation in the nucleus was increased to 6.3% in
the presence of ConA compared with the absence of
ConA in the control. In contrast, the relative intensity
of NF-B (p65) translocation in the nucleus was
decreased considerably, to 8.7%, after the addition of
100 μg/mL ALBE in the presence of ConA compared
with ConA treatment alone. These data demonstrate
that ALBE attenuated NF-B activation and might affect
downstream IL-4 and IL-5 production. ALBE inhibits
ConA-induced phosphorylation of MAP kinases such as
p38, JNK, and ERK (Figure 6). We found that ALBE
attenuated not only the ConA-induced increase in the
activity of NF-B, but also the phosphorylation of
MAPKs and these results suggest that ALBE may pre-
vent allergic and atopic inflammation via NF-B and the
MAPKs signaling pathway.
Discussion
Traditional medicines isolated from natural products
often have positive effects in the prevention and healing
of various immune disorders, such as allergy and atopic
inflammation. In this study, the butanol fraction of
Arctium lappa L. showed potential anti-allergic and anti-
inflammatory effects by decreasing b-hexosaminidase
Figure 2 Effects of ALBE on the proliferation of ConA-induced primary murine splenocytes. Splenocytes were treated with various
concentrations of ALBE and ConA (3 μg/ml) for 72 h. Cell proliferation was assessed using XTT assays. Absorbance was measure data at 450 nm
and 650 nm. Each bar shows the means ± SEM of four independent experiments.
##P < 0.01: significantly different from the untreated group.
**P < 0.01: significantly different from the ConA alone group.
Sohn et al. Clinical and Molecular Allergy 2011, 9:4
http://www.clinicalmolecularallergy.com/content/9/1/4
Page 5 of 11Figure 3 The mRNA expressions and protein secretions of IL-4 by ALBE in primary murine splenocytes. (A) The effects of ALBE on the
mRNA expression of IL-4. ALBE (100 μg/ml) were treated to splenocytes with or without ConA (3 μg/ml) for 16 h. The mRNA expression of IL-4
was assessed by RT-PCR described in method. Each bar shows the means ± SEM of three independent experiments. (B) The effects of ALBE on
the protein secretion of IL-4. ALBE (100 μg/ml) were treated to splenocytes with or without ConA (3 μg/ml) for 16 h. The protein secretion of
IL-4 was assessed by ELISA described in methods. Each bar shows the means ± SEM of four independent experiments.
##P < 0.01: significantly
different from the untreated group. **P < 0.01: significantly different from the ConA alone group.
Sohn et al. Clinical and Molecular Allergy 2011, 9:4
http://www.clinicalmolecularallergy.com/content/9/1/4
Page 6 of 11Figure 4 The mRNA expressions and protein secretion of IL-5 by ALBE in primary murine splenocytes. (A) The effects of ALBE on the
mRNA expression of IL-5. ALBE (100 μg/ml) were treated to splenocytes with or without ConA (3 μg/ml) for 16 h. The mRNA expression of IL-5
was assessed by RT-PCR described in method. Each bar shows the means ± SEM of three independent experiments. (B) The effects of ALBE on
the protein secretion of IL-5. ALBE (100 μg/ml) were treated to splenocytes with or without ConA (3 μg/ml) for 16 h. The protein secretion of
IL-5 was assessed by ELISA described in methods. Each bar shows the means ± SEM of four independent experiments.
##P < 0.01: significantly
different from the untreated group. **P < 0.01: significantly different from the ConA alone group.
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ConA-induced T cells. Mast cells are primary effector
cells involved in the allergic or immediate hypersensitiv-
ity responses [15]. The antigen crosslinking of the IgE-
FcεRI complexes through the aggregation of IgE and
FcεRI on mast cells results in the release of b-hexosami-
nidase, which is a marker of mast cell degranulation. The
release of b-hexosaminidase and histamines also causes
the production of proinflammatory cytokines, such as
IL-4, IL-6, and TNF-a, which can potentiate inflamma-
tory immune responses through the subsequent induc-
tion of other atopic inflammatory mediators. Thus, the
modulation of cytokines in this process is considered a
rational approach for regulating the early phase of aller-
gic responses [5,15].
Atopic dermatitis is characterized by allergic skin
inflammation. Pathological changes in atopic skin are
observed as epidermal thickening and marked infiltra-
tion of inflammatory cells [16]. Atopic dermatitis has
been associated with the Th2 phenotype and dominance
of IL-4, IL-5, and IL-13 secretion [17,18]. We examined
the inhibitory effects of ALBE on ConA-induced prolif-
eration and cytokine (IL-4 and IL-5) secretion of spleno-
cytes, which were used as a marker of Th2 lymphocyte
function, to characterize the T cell immunomodulatory
profile of ALBE. ALBE increased the ConA-induced
proliferation and inhibitory effects on cytokine (IL-4 and
IL-5) secretion in primary murine splenocytes. ALBE
suppressed allergic-related Th2 function by decreasing
the release of IL-4 and IL-5. However, it increased the
total number of T cell subsets (Th1/Th2), indicating
that it might decrease allergic-related Th2 cell function
in some way without suppressing the immune system
because it can augment all T cell subsets.
IL-4 acts as an eosinophil chemoattractant, which
makes endothelial cells produce eosinophil chemotactic
factor and eotaxin [19]. IL-4 is also essential in IgE pro-
duction [20] and the switch from naïve T cells to allergic
Th2 cells [21]. An immunohistochemical examination of
the skin lesions in NC/Nga atopic model mice revealed
the typical features of affected skin observed in patients
with atopic dermatitis, such as increased infiltration of
Figure 5 Effects of ALBE on NF-B activation in ConA-induced primary murine splenocytes. ALBE (100 μg/ml) were treated to splenocytes
with or without ConA (3 μg/ml) for 15 min. After isolation of cytosolic and nuclear fraction, the translocation of NF-B (p65) was assessed by
Western blotting described in methods respectively.
##P < 0.01: significantly different from the untreated group. **P < 0.01: significantly different
from the ConA alone group.
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IL-5 [22,23]. That ALBE can decrease the secretion of
IL-4 and IL-5 released by ConA-induced Th2 cells indi-
cates that it might have a useful effect in allergic and ato-
pic inflammation. We subsequently evaluated the related
mechanisms of ALBE on cytokine secretion, including
NF-B activation and the phosphorylation of MAPKs.
NF-B is a key transcription factor that regulates the
expression of genes involved in immune and inflamma-
tory responses that require inflammatory cytokine pro-
duction. NF-B translocation and the MAPKs pathway
are regarded as important processes in the regulation of
the innate and acquired immune responses and chronic
inflammation [24,25]. NF-B is also a critical transcription
Figure 6 Effects of ALBE on phosphorylations of p38 MAPK in ConA-induced primary murine splenocytes.A L B E( 1 0 0μg/ml) were
treated to splenocytes with or without ConA (3 μg/ml) for 15 min. The phosphorylations of p38 MAP kinase such as p38, JNK and ERK were
assessed by Western blotting described in methods.
#P < 0.05,
##P < 0.01: significantly different from the untreated group. **P < 0.01:
significantly different from the ConA alone group.
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dependent airway inflammation [26].
We detected the inhibitory effects of ALBE on ConA-
induced nuclear translocation of NF-B (p65). Increased
NF-B activity has been reported in asthma, an allergic
disease, and the inhibition of NF-B activity decreased
asthma [25]. Thus, we suggest that ALBE could have an
anti-allergic effect based on the decrease in activated
NF-B it causes. Conventional MAP kinases are classi-
fied into three families: the c-Jun N-terminal kinases
(JNKs), the p38 MAP kinases, and the extracellular sig-
nal-regulated kinases (ERKs). Intracellular signal trans-
duction, including the phosphorylation of p38 MAPK, is
subsequently followed by NF-B translocation, leading
to the production of cytokines and chemokines. We also
showed that ALBE significantly suppressed the ConA-
activated phosphorylation of p38 MAPK in primary
murine splenocytes. It has been reported that p38
MAPK activation can activate transcription factors that
result in the expression of IL-4, IL-5, and IL-13 in
human T cells in response to antigen exposure in aller-
gic disease [25]. The fact that ALBE decreased ConA-
activated MAPKs and mRNA expression of IL-4 and
IL-5 supports the possibility that ALBE may have anti-
allergic and anti-inflammatory effects.
Conclusions
ALBE may exert anti-allergic and anti-inflammatory
activities by suppressing the transcription of NF-Ba n d
the activated MAPKs signal pathway in splenocytes.
Additionally, ALBE inhibited the antigen-induced degra-
nulation of mast cells, as determined by the decreased
release of b-hexosaminidase. From these results, we sug-
gest that ALBE might be useful as a therapeutic agent
for treating various forms of allergic inflammation,
including atopic dermatitis.
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